Having established that the BRAFV600E derived neopeptide KIGDFGLATEK can bind to two HLA class I molecules that are relatively frequent in the Caucasian population, we evaluated whether BRAFV600E mutated LCH-patients expressing HLA-A*03:01 and/or HLA-A*11:01 had increased event-free survival as compared to LCH-patients without these HLA genotypes. The gene discussed is HLA-A; the disease is Langerhans cell histiocytosis.